Stock Research for MACK


Featured Broker: Ally Invest

Get the due diligence for another stock.


MACK Stock Chart & Research Data

The MACK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MACK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MACK Due diligence Resources & Stock Charts

The MACK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MACK Detailed Price Forecast - CNN Money CNN View MACK Detailed Summary - Google Finance
Yahoo View MACK Detailed Summary - Yahoo! Finance Zacks View MACK Stock Research & Analysis -

Stock Analysis

TradeIdeas View MACK Trends & Analysis - Trade-Ideas Barrons View MACK Major Holders - Barrons
NASDAQ View MACK Call Transcripts - NASDAQ Seeking View MACK Breaking News & Analysis - Seeking Alpha
Spotlight View MACK Annual Report - OTC Report View MACK OTC Short Report -
TradeKing View MACK Fundamentals - TradeKing Charts View MACK SEC Filings - Bar Chart
WSJ View Historical Prices for MACK - The WSJ Morningstar View Performance/Total Return for MACK - Morningstar
MarketWatch View the Analyst Estimates for MACK - MarketWatch CNBC View the Earnings History for MACK - CNBC
StockMarketWatch View the MACK Earnings - StockMarketWatch MacroAxis View MACK Buy or Sell Recommendations - MacroAxis
Bullish View the MACK Bullish Patterns - American Bulls Short Pains View MACK Short Pain Metrics -

Social Media Mentions

StockTwits View MACK Stock Mentions - StockTwits PennyStocks View MACK Stock Mentions - PennyStockTweets
Twitter View MACK Stock Mentions - Twitter Invest Hub View MACK Investment Forum News - Investor Hub
Yahoo View MACK Stock Mentions - Yahoo! Message Board Seeking Alpha View MACK Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MACK - Insider Cow View Insider Transactions for MACK - Insider Cow
CNBC View MACK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MACK - OTC Markets
Yahoo View Insider Transactions for MACK - Yahoo! Finance NASDAQ View Institutional Holdings for MACK - NASDAQ

Stock Charts

FinViz View MACK Stock Insight & Charts - StockCharts View MACK Investment Charts -
BarChart View MACK Stock Overview & Charts - BarChart Trading View View MACK User Generated Charts - Trading View

Latest Financial News for MACK

Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials
Posted on Friday October 19, 2018

Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.

Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated
Posted on Friday October 19, 2018

Shares of Merrimack Pharmaceuticals Inc. plummeted 35% toward a record low in premarket trade Friday, after the biopharmaceutical company said it terminated a phase 2 trial of its non-small cell lung cancer treatment after it failed to improve progression free survival. "Since futility was observed, the decision was made to terminate the study," the company said in a statement. Merrimack said it is implementing a review of its drug candidate pipeline, and will provide an update on its Nov. 7 conference call following third-quarter results. The stock had tumbled 50% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF had gained 5.8% and the S&P 500 had tacked on 3.6%.

Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Posted on Friday October 19, 2018

CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. Based on these results, Merrimack is implementing a comprehensive review of its drug candidate pipeline, including assessing the impact of these results on the continued development of MM-121. MM-121 is also currently being evaluated in the SHERBOC study, a Phase 2 clinical trial evaluating MM-121 in combination with fulvestrant, versus fulvestrant alone, in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer.

Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
Posted on Tuesday October 16, 2018

NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.